FGFR2 and intrahepatic cholangiocarcinoma: For ongoing clinical trials, we searched in the clinicaltrials.gov database for recruiting and active, not recruiting trials, using the following keywords: “cholangiocarcinoma”, “intrahepatic cholangiocarcinoma”, “extrahepatic cholangiocarcinoma”, “biliary tract cancer”, “FGFR”, “FGFR2”, “pemigatinib”, “derazantinib”, “infigratinib”, “erdafitinib”, and “futibatinib”.